Crispr

The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

In this video, Lillian L. Siu, MD, FRCPC, discusses two keynote presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses the keynote talk on CRISPR presented at AACR-NCI-EORTC.

The CRISPR/Cas9 gene-editing system is producing results that may transform the treatment of certain diseases, according to Nobel Prize winner Jennifer A. Doudna, PhD.

More than half of patients who received a single dose of CTX110 for relapsed or refractory large B-cell lymphoma responded to therapy, according to topline data released by the agent’s manufacturer.

The CRISPR/Cas9 gene-editing system already is producing results that may fundamentally transform the treatment of certain diseases, according to one of the recipients of the 2020 Nobel Prize in Chemistry.

The FDA cleared an investigational new drug application for NTLA-5001, a T-cell receptor T-cell therapy designed to treat adults with relapsed or refractory acute myeloid leukemia.

The FDA granted fast track designation to VOR33, an engineered allogeneic stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse.

Few scientific advances have generated the optimism and enthusiasm that surround CRISPR.

An analysis of exome sequences in patients with ALS and healthy controls “strongly” indicated that variants in the TP73 gene are associated with risk for ALS, according to study results published in Neurology.